Mercer Global Advisors Inc. ADV grew its stake in Moderna, Inc. (NASDAQ:MRNA – Get Rating) by 7.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,081 shares of the company’s stock after purchasing an additional 1,204 shares during the quarter. Mercer Global Advisors Inc. ADV’s holdings in Moderna were worth $4,338,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in MRNA. Wolff Wiese Magana LLC grew its position in shares of Moderna by 100.0% in the third quarter. Wolff Wiese Magana LLC now owns 152 shares of the company’s stock valued at $58,000 after purchasing an additional 76 shares during the period. Huntington National Bank grew its position in shares of Moderna by 32.9% in the third quarter. Huntington National Bank now owns 319 shares of the company’s stock valued at $122,000 after purchasing an additional 79 shares during the period. Dynamic Advisor Solutions LLC grew its position in shares of Moderna by 7.9% in the third quarter. Dynamic Advisor Solutions LLC now owns 1,512 shares of the company’s stock valued at $582,000 after purchasing an additional 111 shares during the period. GWM Advisors LLC boosted its position in Moderna by 26.9% during the third quarter. GWM Advisors LLC now owns 12,958 shares of the company’s stock worth $4,987,000 after acquiring an additional 2,749 shares during the last quarter. Finally, Vanguard Capital Wealth Advisors acquired a new position in Moderna during the third quarter worth about $322,000. Institutional investors and hedge funds own 60.11% of the company’s stock.
Shares of Moderna stock traded down $3.39 during trading hours on Tuesday, reaching $151.36. 117,634 shares of the company were exchanged, compared to its average volume of 8,088,501. Moderna, Inc. has a 1 year low of $122.01 and a 1 year high of $497.49. The stock’s fifty day moving average is $158.07 and its 200 day moving average is $224.10. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.60 and a current ratio of 1.76. The firm has a market cap of $61.00 billion, a PE ratio of 5.30, a PEG ratio of 0.94 and a beta of 1.55.
In related news, CEO Stephane Bancel sold 9,000 shares of the stock in a transaction on Wednesday, January 19th. The stock was sold at an average price of $188.55, for a total value of $1,696,950.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Juan Andres sold 2,000 shares of the stock in a transaction on Wednesday, February 16th. The shares were sold at an average price of $150.00, for a total value of $300,000.00. The disclosure for this sale can be found here. Insiders sold 206,054 shares of company stock worth $33,851,454 in the last three months. 17.30% of the stock is currently owned by corporate insiders.
A number of equities analysts recently weighed in on the stock. Bank of America upgraded shares of Moderna from an “underperform” rating to a “neutral” rating and boosted their price target for the stock from $135.00 to $180.00 in a research report on Friday, January 21st. TheStreet lowered shares of Moderna from a “b-” rating to a “c+” rating in a research report on Thursday, February 24th. Argus lowered their price target on shares of Moderna from $420.00 to $350.00 in a research report on Thursday, January 6th. Jefferies Financial Group decreased their target price on shares of Moderna from $200.00 to $170.00 in a report on Friday, February 25th. Finally, Morgan Stanley increased their price target on shares of Moderna from $205.00 to $217.00 and gave the company an “equal weight” rating in a research note on Tuesday, April 12th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $242.71.
Moderna Company Profile (Get Rating)
Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics.
- Get a free copy of the StockNews.com research report on Moderna (MRNA)
- Institutional Buying Puts A Bottom In Manpower Group Inc
- Workhorse Johnson & Johnson Plows New All-Time Highs
- Fastenal Stock is Ready to Sprint Higher
- J.B. Hunt Transportation Services Fires On All Cylinders
- 3 No-Brainer Stocks to Buy with $1000
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.